Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias

Annals of Surgery

Volumn 251, Issue 6, 2010, Pages 1034-1040

  Buchwald, Henry ^a   Rudser, Kyle D ^b   Williams, Stanley E ^a   Michalek, Van N ^a   Vagasky, James ^b   Connett, John E ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTERIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CANCER MORTALITY; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIET THERAPY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEALTH PROGRAM; HEART EJECTION FRACTION; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; ILEUM BYPASS; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ADULT; ATHEROSCLEROSIS; CAUSE OF DEATH; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; JEJUNOILEAL BYPASS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME;

EID: 77953021571     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181deb4d0     Document Type: Article

References (21)

1. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat Q. 1988;41:155-178.
2. Minino AM, Arias E, Kochanek KD, et al. Deaths: final data for 2000. Natl Vital Stat Rep. 2002;50:1-119.
3. National Center for Health Statistics, Age-Adjusted Death Rates for Selected Causes, Death Registration States, 1900-1932, and United States, 1933-1998. Available at: http://www.cdc.gov/nchs/datawh/statab/unpubd/mortabs/ hist293.htm. Accessed January 6, 2009.
4. American Heart Association. Heart Disease and Stroke Statistics-2008 Update. Dallas, Texas: American Heart Association; 2008. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3018163. Accessed January 5, 2009.
5. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med. 1990;323:946-955.
6. Buchwald H, Matts JP, Fitch LL, et al. Program on the Surgical Control of the Hyperlipidemias (POSCH): design and methodology. J Clin Epidemiol. 1989;42:1111-1127.
7. Buchwald H, Moore RB, Varco RL. Surgical treatment of hyperlipidemia. Circulation. 1974;49(suppl 5):122-137.
8. Buchwald H, Varco RL, Boen JR, et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Arch Intern Med. 1998;158:1253-1261.
9. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255
10. The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators. Arch Intern Med. 1992;152:1399-1410.
11. Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol. 2000;86:257-262.
12. Strandberg TE, Pyorala K, Cook TJ. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004;364:771-777.
13. LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002;359:1379-1387.
14. Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357:1477-1486.
15. Buchwald H, Williams SE, Matts JP, et al. Overall mortality in the Program on the Surgical Control of the hyperlipidemias. J Am Coll Surg. 2002;195: 327-331.
16. National Death Index, Division of Vital Statistics, National Center for health Statistics. Hyattsville, MD. Available at: http://www.cdc.gov/nchs/ndi. htm. Accessed January 5, 2009.
17. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
18. Kalbfleish JD, Prentice RL. The Statistical Analysis of Failure Time Data. 2nd ed. New York, NY: John Wiley & Sons; 2002.
19. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc Ser B Methodol. 1972;34:187-220.
20. Chen W, Pendyala S, Natarajan V, et al. Endothelial cell barrier protection by simvastatin: GTPase regulation and NADPH oxidase inhibition. Am J Physiol Lung Cell Mol Physiol. 2008;295:L575-L583.
21. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.